Oncotelic Reports that It`s Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
Impressive results in the article but the underlying poster (http://oncotelic.com/wp-content/uploads/AACR-JCA-Glioma-Finalv3.pdf) is a little on the confusing side. They talk about "chemo naive recurrent glioma" but I would assume most patients would get Temodar as newly diagnosed. Where do they find those patients who did not use Temodar? There might be something special about them. Then they go on to show survivals with and without previous Temodar and with and without subsequent Temodar. The best group appears to be the control group and the conclusion is that this treatment is not inferior to Temodar. This might just be that the amount of text on a poster is limited and we have to wait for the published results to completely dissect the trial.
Posted on: 02/13/2019
Click HERE to return to brain tumor news headlines